Applied Therapeutics Inc
NASDAQ:APLT

Watchlist Manager
Applied Therapeutics Inc Logo
Applied Therapeutics Inc
NASDAQ:APLT
Watchlist
Price: 9.625 USD 3.83% Market Closed
Market Cap: 1.1B USD
Have any thoughts about
Applied Therapeutics Inc?
Write Note

Applied Therapeutics Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Applied Therapeutics Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Applied Therapeutics Inc
NASDAQ:APLT
Revenue
$10m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$55.5B
CAGR 3-Years
0%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$28.3B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Revenue
$32.5B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$10.6B
CAGR 3-Years
14%
CAGR 5-Years
24%
CAGR 10-Years
30%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.8B
CAGR 3-Years
1%
CAGR 5-Years
16%
CAGR 10-Years
18%
No Stocks Found

Applied Therapeutics Inc
Revenue Breakdown

Breakdown by Geography
Applied Therapeutics Inc

Not Available

Breakdown by Segments
Applied Therapeutics Inc

Total Revenue: 10m USD
100%
License: 9.2m USD
92.3%
Information Pertaining To Research And Develo...: 774k USD
7.7%

Applied Therapeutics Inc
Glance View

Market Cap
1.1B USD
Industry
Biotechnology

Applied Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 34 full-time employees. The company went IPO on 2019-05-09. The Company’s molecular target is aldose reductase (AR), an enzyme that converts glucose to sorbitol under oxidative stress conditions. Its product candidates include AT-007, AT-001, AT-003 and AT-104. The Company’s AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. AT-001 is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), fatal fibrosis of the heart. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). AT-104 is a dual selective PI3K inhibitor in preclinical development for T Cell Acute Lymphoblastic Leukemia (T-ALL).

APLT Intrinsic Value
6.71 USD
Overvaluation 30%
Intrinsic Value
Price

See Also

What is Applied Therapeutics Inc's Revenue?
Revenue
10m USD

Based on the financial report for Dec 31, 2023, Applied Therapeutics Inc's Revenue amounts to 10m USD.

Back to Top